Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan

Clinical trials showed pangenotypic direct-acting antivirals’ (DAAs) excellent efficacy and safety when treating hepatitis C virus (HCV). Two pangenotypic regimens were examined, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), in a real-world Taiwanese setting, including all...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Kao-Chi, Tung, Shui-Yi, Wei, Kuo-Liang, Shen, Chen-Heng, Hsieh, Yung-Yu, Chen, Wei-Ming, Chen, Yi-Hsing, Chen, Chun-Hsien, Yen, Chi-Wei, Xu, Huang-Wei, Tung, Wei-Lin, Hung, Chao-Hung, Lu, Sheng-Nan, Chang, Te-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241842/
https://www.ncbi.nlm.nih.gov/pubmed/34188161
http://dx.doi.org/10.1038/s41598-021-93095-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241842/
https://www.ncbi.nlm.nih.gov/pubmed/34188161
http://dx.doi.org/10.1038/s41598-021-93095-x

Ejemplares similares